Background: Haemodynamic instability (HI) represent the most important intra-operative manifestation of major complications occurring during TAVI. The aim of this study was to investigate the causes, risk factors and clinical significance of HI during TAVI. Methods: From November 2007 to September 2013 all patients consecutively treated in our center were included. HI was defined as a drop of mean arterial pressure ! 20 mmHg with a heart rate ! 100 or 50 beats/min for ! 1 min. Causes of HI were classified in those occuring post-preparatory balloon aortic valvuloplasty (PBAV) and post-valve implantation (VI). Each group was compared with a control group where HI did not occur. Outcomes were assessed according to VARC 2 criteria at 30 days, 1 and 2 years. Results: Overall, of 538 patients that underwent TAVI, 35 (7.4%) developed HI. Of these 18/453 (3.9%) developed HI after PBAV, while 19/538 (3.5%) developed HI after VI. Causes of HI after PBAV included severe aortic regurgitation (AR; n ¼ 12/ 18; 66.6%), new-onset tachy-or brady-arrhythmia (n ¼ 4/18; 22.2%), aortic annulus rupture (n ¼ 1/18; 5.5%) and cardiac tamponade (n ¼ 1/18; 5.5%). Causes of HI after VI included aortic dissection (n ¼ 2/19; 10.5%), cardiac tamponade (n ¼ 14/19; 73.6%), coronary obstruction (n ¼ 2/19; 10.5%) and severe AR (n ¼ 1/19; 5.2%).
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Patients that developed HI after PBAV had greater all-cause and cardiovascular mortality at 30 days (respectively, 11.1% vs. 3%, p ¼ 0.023; and 11.1% vs. 1.8%, p ¼ 0.009) while no differences were found in all-cause and cardiovascular mortality at 2 years of follow-up. Conversely patients that developed HI after implantation had higher rates of all-cause and cardiovascular mortality at 30 days (respectively, 26.3% vs. 2.7%, p < 0.001; and 21.1% vs. 1.9%, p < 0.001) and at 2-year follow-up (respectively, 36.8% vs. 16.9%, p ¼ 0.025; and 26.3% vs. 9.3%; p ¼ 0.015). Conclusions: HI can occur both after PBAV and VI. The most common cause of HI after PBAV were severe AR. Conversely, the most common after VI was cardiac tamponade. HI after PBAV was associated with a higher 30-day mortality but did not affected long-term survival.
TCT-777
The Background: Vascular complications (VC) during transcatheter aortic valve implantation (TAVI) are reported using various criteria and several access site approaches. We aimed to describe the prevalence of VC associated with TAVI via a solely percutaneous trans-femoral approach and their predictive value for survival, using both the updated Valve Academic Research Consortium-2 (VARC-2) criteria and the former VARC-1 criteria. Methods: Between March 2009 and September 2013, 403 consecutive patients at a mean age (AESD) of 83AE6 underwent percutaneous trans-femoral TAVI. All procedures were performed using an 18/19 Fr. sheath. Vascular complications were defined by both VARC-1 and VARC-2 criteria and analyzed separately. Results: VARC-1 and VARC-2 defined VC occurred in 71 (18%) and 78 (19%) patients, respectively, with 15 (4%) and 33 (8%) defined as major VC. The difference in frequency of major and minor VC was mainly driven by VARC-2 implementation of major bleeding events. With either VARC definition, patients with minor VC had similar mortality and complications rates as those patients without VC. In multivariate analyses, referenced to patients with minor or no VC, only VARC-1 defined major VC were significantly associated with increased mortality (HR 3.52; CI 1.5-8.4; p¼0.005), whereas VARC-2 defined major VC were found to be only marginally significant (HR 1.9; CI 0.9-3.9; p¼0.08). Conclusions: The VARC-2 VC criteria increase the observed rate of major VC following TAVI mainly by the inclusion of major bleeding events, and by doing so decrease their predictive usefulness on patient outcomes. We searched databases for Edwards SAPIEN TAVR studies comparing the TF and TA approaches regarding the following outcomes: 30-day and 1-year mortality; 30-day stroke; 30-day permanent pacemaker implantation; and 30-day vascular complications. The outcomes were then compared between the PARTNER trial and the pooled data from remaining studies. Results: The PARTNER trial had 244 TF and 104 TA patients. In the pooled data from 17 studies, TA patients had a significantly higher EuroSCORE as compared to TF patients (24.6AE12.9 vs 21.3AE12.0; p< 0.001). In the intention-to-treat analysis of the PARTNER study the EuroSCORE was not significantly different between the TA and TF groups (29.8AE15.9 vs 29.1AE 16.1; p¼0.61). As shown in Table 1 , 30-day and 1-year mortality were similar between the two approaches in the PARTNER trial; conversely, pooled results showed a significantly decreased risk with the TF approach. The PARTNER trial and remaining studies showed an increased incidence of 30-day vascular complications in the TF arm and a similar risk of 30-day stroke incidence and new pacemaker insertion between accesses.
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Conclusions: The observed difference in mortality is likely secondary to the effect of randomization in the PARTNER trial with comparable pre-procedure mortality risk scores between the TA and TF arms. A reduction in the relative risk of vascular complications in the TF arm in the pooled data vs PARTNER trial is likely due to improvement in overall screening, valves with smaller delivery sheath, and increasing operator expertise.
TCT-779
Characterization Background: In patients with aortic stenosis (AS), mitral regurgitation (MR) is a common finding. While surgical treatment of AS has been shown to result in a decrease in MR severity, little is known regarding outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to characterize the shortand mid-term impact of the procedure on MR grade. Methods: We studied our TAVI patients and assessed the severity of MR at baseline, 1 month and 6 months after the procedure. Trans thoracic echocardiographic studies were performed using a Philips IE33 by an experienced sonographer and reviewed by a cardiologist specializing in echocardiography. Results: 261 patients were included in the analysis(mean age 82.1AE6.9 years, 59% female). 74 patients (28.4%) had mild to moderate MR or above at baseline. In this group, there was a mean reduction of 0.9AE0.97 in the degree of regurgitation after 1 month and 1.2AE1.1 after six months (p< 0.01). In patients with moderate MR or above (n¼26, 10% of the cohort), the respective improvement rates were 1.5AE1.1 and 1.8AE1.4 (p< 0.01). Improvement of MR (1+ or greater) at six months was identified in 40/74 (54.1%) of patients with mild-moderate MR or above, and in 23/26 (88.5%) of those with moderate MR or above, and was associated with improved functional class (correlation coefficient -0.294, p< 0.001). www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5 :00 PM-7:00 PM JACC Vol 64/11/Suppl B j September 13-17, 2014 j TCT Abstracts/Valvular disease -Aortic: TAVR B227
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